Reference
- Karlowski JA, Draghi AD, Thornsberry C, Jones ME, Critchley IA, Sahm DE, Antimicrobial susceptibilities of Streptococcus pneumoniae ILemophilus intluenzae and Moraxella catarrhalisisolated in two successive respiratory seasons in the US. Inter. Antimiavb. Agents 20,76–85 (2002).
- Telithromycin (Ketek°). January 2003 NCCLS Presentation, Tampa, Florida.
- Hakenbeck R. Mosaic genes and their role inpenicillin-resistant Stleptococcus pneumoniae. Dectivphomsis19, 597–601 (1998).
- Kaye CM, Allen A, Perry S, etal. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillinklavulanate. Clin. Themp. 23, 578–584 (2001).
- Goossens H. Mystic Study Group Europe, 2001, MYSTIC program; summary of European data from 1997 to 2000. Di. Mcrobiol Infect. Dis. 41,183-189 (2001).
- Bradford P Extended-spectrum 13-lactamases in the 21st century: characterization, epidemiology and detection of this important resistance threat. Gun. IlArobiol. Revs. 14, 933–951 (2001).
- Gruteke P, Goessens W van Gus J, etal. Patterns of resistance associated with integrons, the extended-spectrum 0-lactamase SHV-5 gene and a multidrug efflux pump of Vebsiella pneumoniae causing a nosocomial outbreak, J. Clin. 11/licrobiol 41,1161-1166 (2003).
- Morbidity, Mortality Weekly Report, 2002, Public health dispatch: vancomycin-resistant Staphylococcus aureus — Pennsylvania, 2002, CDC MIVIWR, 51, 902–903 (2002).